Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
In a Phase II trial, pelacarsen reduced Lp(a) levels by 3558% depending on the dose, with no significant differences in safety indicators compared with the placebo
Transgenic mice in which GCLC expression is abolished in hepatocytes have 58% of normal hepatic GSH levels and manifest liver pathologies characteristic of the various clinical stages of fatty liver disease 8,9
Recent studies have demonstrated that inhibiting various steps of TMAO production can reduce TMAO levels and treat AS (9, 8588) (Figure 4)
it is also crucial for detoxification and cellular health
US$ 21.05
US$ 27.35
US$ 20.88
US$ 29.95
